Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 5;46(7):7048-7064.
doi: 10.3390/cimb46070420.

Unraveling the Immune Microenvironment in Diffuse Large B-Cell Lymphoma: Prognostic and Potential Therapeutic Implications

Epameinondas Koumpis  1 , Alexandra Papoudou-Bai  2 , Konstantina Papathanasiou  1 , Evangelos Kolettas  3   4 , Panagiotis Kanavaros  5 , Eleftheria Hatzimichael  1
Affiliations
Review

Unraveling the Immune Microenvironment in Diffuse Large B-Cell Lymphoma: Prognostic and Potential Therapeutic Implications

Epameinondas Koumpis et al. Curr Issues Mol Biol. .

Abstract

Diffuse large B cell lymphoma (DLBCL) is a multifaceted condition characterized by significant diversity in its molecular and pathological subtypes and clinical manifestation. Despite the progress made in the treatment of DLBCL through the development of novel drugs, an estimated one-third of patients encounter relapse or acquire refractory disease. The tumor microenvironment (TME) of DLBCL, a complex network consisting of cellular and noncellular components that engage in interactions with the tumor, is a parameter that is gaining increasing attention. The TME comprises both the immune and nonimmune microenvironments. The immune microenvironment comprises natural killer (NK) cells, dendritic cells (DCs), tumor-associated macrophages (TAMs), neutrophils, myeloid-derived suppressor cells (MDSCs), and T and B lymphocytes. The nonimmune microenvironment consists of the extracellular matrix (ECM), cancer-associated fibroblasts (CAFs), mesenchymal stromal cells, and other molecules that are secreted. Despite ongoing research, the exact impact of these components and their interaction on the progression of the disease remains elusive. A comprehensive review of significant discoveries concerning the cellular and noncellular constituents, molecular characteristics, and treatment response and prognosis of the TME in DLBCL, as well as the potential targeting of the TME with novel therapeutic approaches, is provided in this article.

Keywords: DLBCL; TME; lymphoma; microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Components of immune and nonimmune microenvironment in DLBCL.
Figure 2
Figure 2
The polarization of macrophages in tumor microenvironment. LPS: lipopolysaccharides, IFN: interferon, TNF: tumor necrosis factor, IL: interleukin, TGF: tumor growth factor, HLA: human leukocyte antigen.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Sehn L.H., Salles G. Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2021;384:842–858. doi: 10.1056/NEJMra2027612. - DOI - PMC - PubMed
    1. Tilly H., Morschhauser F., Sehn L.H., Friedberg J.W., Trněný M., Sharman J.P., Herbaux C., Burke J.M., Matasar M., Rai S., et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2022;386:351–363. doi: 10.1056/NEJMoa2115304. - DOI - PubMed
    1. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511. doi: 10.1038/35000501. - DOI - PubMed
    1. Bea S., Zettl A., Wright G., Salaverria I., Jehn P., Moreno V., Burek C., Ott G., Puig X., Yang L., et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005;106:3183–3190. doi: 10.1182/blood-2005-04-1399. - DOI - PMC - PubMed
    1. Meyer P.N., Fu K., Greiner T.C., Smith L.M., Delabie J., Gascoyne R.D., Ott G., Rosenwald A., Braziel R.M., Campo E., et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J. Clin. Oncol. 2011;29:200–207. doi: 10.1200/JCO.2010.30.0368. - DOI - PMC - PubMed

Grants and funding

This research received no external funding.

LinkOut - more resources